Opus’ LYNX-2 Phase III Trial Hits Primary Endpoint for Post-LASIK Night Vision Treatment
Opus’ phentolamine eye drops hit the LYNX-2 letter-gain target on mesopic low contrast distance visual acuity. Opus Genetics (North Carolina,…
Illuminating Vision: The Latest Advances in Light Adjustable Lens™ Technology at the 2025 ASCRS Annual Meeting
Sponsored by RxSight® Experts highlight real-world applications of the Light Adjustable Lens™ (LAL®/LAL+®) for optimized cataract outcomes. On Day 3…
latest posts
